Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24535255 | 0.92 | — | — | |
| SCHEMBL352021 | 0.84 | TSHR (0.33) | — | |
| SCHEMBL370091 | 0.83 | — | — | |
| SCHEMBL351419 | 0.82 | KDM4E (0.33) | MEN1CYP1A2HPGDCYP2C19KMT2A | |
| SCHEMBL350079 | 0.82 | NSD2 (0.32) | — | |
| SCHEMBL10177366 | 0.81 | SMN1; SMN2 (0.34) | MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL10177367 | 0.81 | NSD2 (0.36) | — | |
| SCHEMBL408863 | 0.77 | S1PR1 (0.33) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL352304 | 0.77 | HTR7 (0.36) | MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL16767936 | 0.77 | NSD2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9669399-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160263566-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2016-09-15 | — | — | US | disclosed |
| US-9381508-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9266913-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150360215-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2015-12-17 | — | — | US | disclosed |
| US-9200021-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150152126-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
| US-8975443-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140371446-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8841487-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371446-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PPIP5K2, ITPA | MEN1 946/4885CYP1A2 2321/4885CYP2D6 1282/4885 |
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | MEN1 1326/4885CYP1A2 3435/4885CYP2D6 2522/4885 |
| US-20160263566-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | MEN1 1326/4885CYP1A2 3435/4885CYP2D6 2522/4885 |
| US-20150152126-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | MEN1 1326/4885CYP1A2 3435/4885CYP2D6 2522/4885 |
| US-20150360215-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | MEN1 1326/4885CYP1A2 3435/4885CYP2D6 2522/4885 |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PPIP5K2, ITPA | MEN1 946/4885CYP1A2 2321/4885CYP2D6 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.